The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
A bidding war has netted Sarepta the largest-ever licensing deal for a cell or gene therapy. Can Roche make it work?
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
The French drugmaker bets big as it plays catch-up in the immuno-oncology space with a next-generation IL-2 buyout.
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.